

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Trimethylamine N-oxide does not impact viability, ROS production and mitochondrial membrane potential of adult rat cardiomyocytes

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1704694> since 2022-05-13T10:27:19Z

Published version:

DOI:10.3390/ijms20123045

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



1 *Research Article*

2 **Trimethylamine N-oxide does not impact viability,** 3 **ROS production and mitochondrial membrane** 4 **potential of adult rat cardiomyocytes**

5 **Giulia Querio ¹, Susanna Antoniotti ¹, Renzo Levi ¹ and Maria Pia Gallo ^{1,*}**

6 ¹ Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123,
7 Turin, Italy

8 * Correspondence: mariapia.gallo@unito.it; Tel.: +390116704671

9

10 **Abstract:** Trimethylamine N-oxide (TMAO) is an organic compound derived from dietary choline
11 and L-carnitine. It behaves as an osmolyte, a protein stabilizer and an electron acceptor, showing
12 different biological functions in different animals. Recent works point out that in humans high
13 circulating levels of TMAO are related with the progression of atherosclerosis and other
14 cardiovascular diseases. Nevertheless, studies on a direct role of TMAO on cardiomyocytes
15 parameters are still limited. This work focuses on the effects of TMAO on isolated adult rat
16 cardiomyocytes. TMAO both 100µM and 10mM, from 1 to 24 h of treatment, does not affect cell
17 viability, sarcomere length, intracellular ROS and mitochondrial membrane potential. Furthermore,
18 the simultaneous treatment with TMAO and known cardiac insults, H₂O₂ or Doxorubicin, does not
19 affect the effect of the treatment. In conclusion, TMAO cannot be considered a direct cause or an
20 exacerbating risk factor of cardiac damage at the cellular level in acute conditions.

21 **Keywords:** Trimethylamine N-oxide; cardiomyocytes; cardiotoxicity; ROS; mitochondrial
22 membrane potential
23

24 **1. Introduction**


25 Trimethylamine N-oxide (TMAO) is an amine oxide directly introduced through the diet or
26 synthesized from its precursors, primarily L-carnitine and choline, that are transformed into
27 trimethylamine (TMA) by the gut microbiota. Once absorbed, TMA in most mammals is oxidized by
28 hepatic FMOs to form TMAO which enters the systemic circulation. Several studies illustrates
29 different biological functions of TMAO in other animals. In elasmobranchs and deep sea fishes it acts
30 as an osmolyte able to counteract either osmotic or hydrostatic pressure. It is a protein stabilizer
31 preserving protein folding and it also acts as an electron acceptor balancing oxidative stress [1,2].
32 TMAO is also reduced to TMA in the anaerobic metabolism of a number of bacteria. Although TMAO
33 is involved in several reactions within cells, recent studies highlight its detrimental role when present
34 in high plasmatic concentrations in some mammals. In fact, TMAO seems to be involved in
35 accelerating endothelial cell senescence, enhancing vascular inflammation and oxidative stress [3,4];
36 it also could be involved in the stimulation of platelets hyperreactivity and in the onset of thrombosis,
37 exacerbating atherosclerotic lesions [5]. Several studies also underline the role of TMAO in the
38 pathogenesis of type 2 diabetes mellitus [6]. There are limited data on its function in mediating direct
39 cardiac injuries, and they are mainly focused on its role in the impairment of mitochondrial
40 metabolism [7] and calcium handling [8]. Instead, recent papers revalue the role of TMAO,

41 underlining the emerging debate on its direct effect in causing or exacerbating cardiovascular
42 diseases (CVD) [9,10]. First criticisms point out that populations that have diets with high
43 concentrations of TMAO, like those rich in fish products, when compared to Western diets rich in its
44 precursors, have reduced risks of CVD or diseases assumed to be related to high TMAO plasma levels
45 [11]. Another study demonstrate that TMAO does not affect macrophage foam cells formation and
46 lesion progression in ApoE^{-/-} mice expressing human cholesteryl ester transfer protein, suggesting
47 that the molecule does not worsen atherosclerosis [12]. Furthermore, administration of TMAO seems
48 to ameliorate symptoms related to streptozotocin induced diabetes in rats and mice, highlighting
49 no direct contribution of the molecule in exacerbating this condition [13]. Finally, data about TMAO
50 plasma concentrations in health and pathological subjects are not clear: lack of plasma concentration
51 ranges of the molecule highlights the difficulties in referring to TMAO as a protective or a damaging
52 factor in CVD. Starting from these conflicting considerations, aim of this work is to evaluate for the
53 first time the effect of TMAO in an *in vitro* model of adult rat cardiomyocytes exposed to different
54 concentrations of the compound from 1 h to 24 h of treatment. To show whether TMAO exacerbates
55 or reduces induced cell stress, cardiomyocytes are simultaneously treated with TMAO and H₂O₂ or
56 Doxorubicin (DOX). Investigations have been focused to cell viability after TMAO or TMAO and
57 stressors co-treatment, assessing cell morphology and functionality with α -actinin staining and
58 specific probes that measure oxidative stress status and mitochondrial membrane potential.

59 2. Results

60 2.1 TMAO and cell viability

61 In order to investigate the effect of TMAO on cell viability, cardiomyocytes are treated with
62 TMAO 100 μ M, TMAO 10mM, H₂O₂ 50 μ M and H₂O₂ 50 μ M+TMAO 100 μ M. After 1 h or 24 h of
63 treatment, cardiomyocytes are labeled with PI and marked nuclei of suffering cells are detected by
64 confocal microscopy at 568nm. Concentrations used have been taken from literature: TMAO 100 μ M
65 is recognized as a marker of cardiovascular risk, TMAO 10mM is over the physiological range and
66 here tested to detect any effect induced by high concentrations of the compound [14]. As shown in
67 Figure 1a, there is no effect of TMAO 100 μ M nor TMAO 10mM at either time of treatment, while
68 H₂O₂, here used as positive control, has effects only after 24 h. Simultaneous treatment with H₂O₂ and
69 TMAO does not ameliorate nor worsen the effect of the stressor on cell viability (1 h: CTRL:
70 83.95 \pm 6.59, n=3, 52 cells; TMAO 100 μ M: 85.52 \pm 7.01, n=5, 81 cells; TMAO 10mM: 84.08 \pm 5.84, n=5, 92
71 cells; H₂O₂: 52.92 \pm 16.46, n=3, 56 cells; H₂O₂+TMAO: 50.93 \pm 18.50, n=3, 58 cells. 24 h: CTRL: 83.42 \pm 2.29,
72 n=3, 101 cells; TMAO 100 μ M: 85.66 \pm 6.48, n=3, 91 cells; TMAO 10mM: 62.22 \pm 10.47 n=3, 119 cells; H₂O₂:
73 2.38 \pm 2.38, n=3, 82 cells(**P<0.001); H₂O₂+TMAO: 1.33 \pm 1.33, n=3, 41 cells(**P<0.001)). Figure 1b displays
74 confocal images of cardiomyocytes from a representative experiment of PI staining after 24 h of
75 treatment. White arrows point out PI-stained, damaged cardiomyocytes.




76
77

78 **Figure 1.** Cell viability after TMAO exposure. a) Bar graph of cell viability after 1 h and 24 h of
79 treatment. Cells viability results reduced only after H₂O₂ treatment for 24 h, condition not ameliorated
80 nor worsened by the simultaneous treatment with TMAO (refer to the main text for numerical values).
81 b) Merged images in bright field and fluorescence of cells treated for 24 h with TMAO 100 μM and
82 TMAO 10 mM, H₂O₂ and H₂O₂ + TMAO and labeled with propidium iodide (PI) (20X magnification).
83 White arrows point out PI-stained, damaged cardiomyocytes.

84 **2.2 TMAO and sarcomere length**

85 To evaluate if TMAO is able to alter sarcomere structures after 24 h of treatment, sarcomere
86 length is measured in α-actinin stained cardiomyocytes. As shown in Figure 2, no changes in
87 sarcomere length are observed in cells treated with TMAO, while H₂O₂ 50 μM used as a positive
88 control, cause cardiomyocytes shrinkage, condition that is not ameliorated nor worsened by the
89 simultaneous treatment with TMAO. In cardiomyocytes treated with DOX 1 μM for 24 h we do not
90 observe sarcomere length variations, as in our model DOX treatment is designed to induce a mild
91 damage preceding cell shortening. Even so, 100 μM TMAO does not modify DOX-treated
92 cardiomyocytes (sarcomere length in μm is: CTRL: 1.69±0.01, n=7, 42 cells; TMAO 100 μM: 1.69±0.01,
93 n=6, 34 cells; TMAO 10 mM: 1.67±0.02, n=3, 19 cells; H₂O₂: 1.22±0.04, n=5, 33 cells (**P<0.001);
94 H₂O₂+TMAO: 1.28±0.03, n=3, 24 cells (**P<0.001); DOX: 1.62±0.02, n=3, 16 cells; DOX+TMAO:
95 1.65±0.01, n=3, 15 cells).




96
97
98
99
100

Figure 2. Sarcomere length after TMAO treatment. a) Confocal microscopy images of fixed cells labeled for α -actinin protein (40X magnification). b) Bar graph showing sarcomere length after 24 h of treatment with TMAO and other stressors: no cell shrinkage is measured when cells are exposed to different TMAO concentrations (refer to the main text for numerical values).

101
102
103
104
105
106
107
108
109
110
111

2.3 TMAO and intracellular Reactive Oxygen Species (ROS)

In order to determine a variation in total ROS produced after treatment with TMAO for 1 h, 3 h or 24 h, cells are labeled with DCF-DA probe and its fluorescence is quantified and related to control. As shown in Figures 3 (1 h, 3 h) and 4 (24 h) no fluorescence variations after TMAO treatment is detected at any concentration and time used. As a positive control we employ DOX 1 μ M for 24 h [15]; this drug caused a significant variation in ROS production referred to control condition. TMAO 100 μ M does not modify ROS production in DOX treated cardiomyocytes (Fig. 4). (1h: TMAO 100 μ M: 1.30 \pm 0.21, n=3, 34 cells; TMAO 10mM: 1.32 \pm 0.23, n=3, 40 cells, vs CTRL; 3h: TMAO 100 μ M: 0.96 \pm 0.05, n=3, 45 cells; TMAO 10mM: 1.15 \pm 0.09, n=3, 52 cells, vs CTRL; 24h: TMAO 100 μ M: 1.18 \pm 0.04, n=5, 40 cells; TMAO 10mM: 1.24 \pm 0.16, n=3, 52 cells; DOX: 1.33 \pm 0.11, n=4, 21 cells (**P<0.01); DOX+TMAO: 1.27 \pm 0.01, n=6, 31 cells (**P<0.001) vs CTRL).



112

113

114


115

116

117

118

Figure 3. ROS production after 1 h and 3 h of treatment. a) Confocal microscopy images of cells treated with TMAO 100µM and TMAO 10mM for 1 h and 3 h and labeled with DCF-DA probe (60X magnification). b) Bar graph showing mean fluorescence after 1 h and 3 h of treatment, no variations or ROS produced are detectable (refer to the main text for numerical values).



119

120

121 **Figure 4.** ROS production after 24 h of treatment. a) Confocal microscopy images of cells treated with
 122 TMAO 100µM and TMAO 10mM for 24 h and labeled with DCF-DA probe. In these experiments
 123 Doxorubicin (DOX) is used as positive control (60X magnification). b) Bar graph showing mean
 124 fluorescence after 24 h of treatment. No variations of ROS produced are detectable after TMAO
 125 treatment, and a small but significant increase is visible after DOX treatment (here used as positive
 126 control), this increase is not changed by a simultaneous treatment with TMAO (refer to the main text
 for numerical values).

127

2.4 TMAO and mitochondrial membrane potential

128

129

130


131

132


133

To investigate the potential metabolic damage induced by TMAO, cardiomyocytes treated with
 TMAO 100µM and 1mM for 1 h, 3 h or 24 h are labeled with the JC-1 probe. Figures 5 (1 h, 3 h) and 6
 (24 h) show variations in mitochondrial membrane potential (red/green fluorescence ratio) detected
 by confocal microscopy in living cells. TMAO treatment from 1 to 24 h does not cause any difference
 towards control, indicating no mitochondrial effect of the molecule, while, as expected, DOX cause a
 depolarization of mitochondrial membrane potential after 24 h of treatment. TMAO 100µM does not

134 modify mitochondrial membrane potential in DOX treated cardiomyocytes (Fig. 6) (1 h: TMAO
 135 100µM: 1.09±0.08, n=5, 65 cells; TMAO 10mM: 1.11±0.11, n=3, 49 cells, vs CTRL. 3 h: TMAO 100µM:
 136 1.02±0.06, n=3, 26 cells; TMAO 10mM: 0.88±0.05, n=4, 39 cells, vs CTRL; 24 h: TMAO 100µM: 1.08±0.11,
 137 n=3, 21 cells; TMAO 10mM: 0.95±0.15, n=3, 54 cells; DOX: 0.73±0.02, n=3, 24 cells (**P<0.01);
 138 DOX+TMAO: 0.69±0.05, n=3, 22 cells (**P<0.01), vs CTRL).
 139



140
 141 **Figure 5.** Mitochondrial membrane potential variation following 1 h and 3 h of treatment. a) Confocal
 142 microscopy images of cells treated with TMAO 100µM and TMAO 10mM for 1 h and 3 h and labeled
 143 with JC-1 probe (60X magnification). b) Bar graph showing red/green fluorescence after 1 h and 3 h
 144 of treatment, no variations of mitochondrial membrane potential is detected (refer to the main text for
 145 numerical values).



146

147

148

149

150

151

152

153

154

155

156

157

158

Figure 6. Mitochondrial membrane potential variation following 24 h treatment. a) Confocal microscopy images of cells treated with TMAO 100µM and TMAO 10mM for 24 h and labeled with JC-1 probe. In these experiments Doxorubicin (DOX) is used as positive control (60X magnification). b) Bar graph showing red/green fluorescence after 24 h of treatment, no variations of mitochondrial membrane potential is detected, a little but significant reduction of the ratio is visible after DOX treatment here used as positive control, condition not changed in a simultaneous treatment with TMAO (refer to the main text for numerical values).

3. Discussion

This study provides novel insights into the physiological role of TMAO on isolated adult rat cardiomyocytes. Our findings do not show effects of TMAO on cell viability, sarcomere length, ROS

159 production and mitochondrial membrane potential within the range of concentration used.
 160 Moreover, we demonstrate that TMAO does not exacerbate or counteract the effect of known insults
 161 such as H₂O₂ or Doxorubicin, tested for up to 24 h of treatment. Taken together these results suggest
 162 that TMAO should not be considered a primary cause of acute cardiac damage and that the molecule
 163 could not revert or worsen existing risk factors of cardiac damage.

164 In the last few years, many studies suggest a strong relationship among diet, gut microbiota and
 165 cardiovascular diseases [16]. In particular, some attention has been pointed to either TMAO directly
 166 coming from diet (fish), or produced from L-carnitine and choline conversion by gut microbiota into
 167 TMA and oxidized in the liver by FMO3 enzymes [17, 14].

168 Experiments have mainly now focused on endothelial cells damaging role of TMAO. It has been
 169 described to upregulate cellular senescence reducing cell proliferation, increasing the expression of
 170 senescence markers, as p53 and p21, and impairing cell migration [3]. TMAO also increases
 171 endothelial cells oxidative stress through a down-regulation of SIRT-1 and impairs NO production
 172 that causes endothelial dysfunction [4]. ~~Prolonged hypertensive~~Hypertensive effects of TMAO
 173 and angiotensin II have been evaluated by Ufnal and colleagues who demonstrate that TMAO has a role
 174 in stabilizing the action of Ang II and in prolonging its hypertensive effect, underlining the role of
 175 TMAO in stabilizing protein conformation and no direct role of the molecule in mediating
 176 hypertension, promoting this condition [18]. Koeth and colleagues underline the strong relationship
 177 among high consumption of TMAO precursors, high TMAO plasma concentrations and the
 178 development of atherosclerosis [19], while another study underlines the effect of the metabolite in
 179 enhancing platelet hyperreactivity and thrombosis risk in subjects with high TMAO plasma
 180 concentrations [5]. In relation with cardiovascular effects of TMAO, Dambrova and collaborators
 181 evidence that high plasma concentrations of the molecule are linked with increased body weight,
 182 insulin resistance and it directly correlates with an augmented risk of diabetes [20].

183 Only a few studies are centered on the direct effect of the molecule on cardiac cells; in particular
 184 they focus on the impairment of mitochondrial metabolism in the heart and underline TMAO as an
 185 agent that increases the severity of cardiovascular events or that enhances the progression of
 186 cardiovascular diseases [7]. Savi et colleagues show a damaging effect of TMAO in cardiomyocytes
 187 because it worsens intracellular calcium handling with a reduced efficiency in the intracellular
 188 calcium removal and consequent loss in functionality of cardiac cells, furthermore TMAO seems to
 189 alter energetic metabolism and to facilitate protein oxidative damage [8].

190 This scenario presents TMAO as either a marker or a direct agent involved in vascular and
 191 cardiac outcomes, but recent papers seem to oppose this point of view, highlighting uncertainty about
 192 the causative relation between TMAO and CVD [9]. It is still debated the function of TMAO that is,
 193 for example, controversial in fish-rich diets, because of the higher bioavailability of the compound in
 194 seafood products and their well-known role in lowering risk of CVD. Also, TMAO does not enhance
 195 atherosclerosis development because it seems not to be involved in foam cell formation even at higher
 196 concentrations than physiological ones [12], and, there is no direct correlation between high plasma
 197 TMAO concentrations and coronary heart diseases [21, 22]. Last findings by Huc et al., underline also
 198 a protective role of TMAO in reducing diastolic dysfunction and fibrosis in pressure-overloaded heart
 199 [23].

200 The present study fits into this debate and the results presented agree with other works
 201 supporting TMAO as a non-damaging factor. In fact, it is well known that loss of vital cardiac cells is
 202 a damaging condition that hampers primarily the functionality of the heart and has several
 203 aggravating responses also in peripheral tissues. Our first investigations underline no toxic effect in
 204 cardiomyocytes exposed to high concentrations of TMAO highlighting that the molecule is not
 205 involved in inducing cardiac tissue cells loss (Fig. 1), and, no alterations of cardiac structure emerge
 206 from the evaluation of sarcomere length and cytoskeletal organization (Fig. 2). Oxidative stress could
 207 be considered one of the causative factors of senescence in cells, and one of the promoters of
 208 cardiometabolic reorganization in response to injury. Considering TMAO as a possible inducer of
 209 ROS rising, both in cytoplasmic and mitochondrial environment, we show no variation in ROS
 210 production even after 24 h of treatment (Fig. 3 and 4) and we detect no depolarization of

Formatted: Strikethrough

Formatted: Strikethrough

Formatted: Strikethrough

Formatted: Strikethrough

Formatted: Font color: Red, Subscript

Formatted: Strikethrough

Formatted: Strikethrough

Formatted: Strikethrough

211 mitochondrial membrane potential underlying no direct influence of the molecule in inducing cardiac
212 cell senescence (Fig. 5 and 6).

Formatted: Strikethrough

213 4. Materials and Methods

214 4.1 Animal care and sacrifice

215 Experiments are performed on female adult rats which are allowed *ad libitum* access to tap water
216 and standard rodent diet. The animals receive human care in compliance with the Guide for the Care
217 and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication
218 No. 85-23, revised 1996), and in accordance with Italian law (DL-116, Jan. 27, 1992). The scientific
219 project is supervised and approved by the Italian Ministry of Health, Rome, and by the ethical
220 committee of the University of Torino. Rats are anaesthetized by i.p. injection of Pentobarbital
221 (Nembutal, 100 mg/Kg) and killed by stunning and cervical dislocation.

222 4.2 Solutions and drugs

223 Tyrode standard solution ~~contains~~containing (in mM): 154 NaCl, 4 KCl, 1 MgCl₂, 5.5 D-glucose,
224 5 HEPES, 2 CaCl₂, pH adjusted to 7.34 with NaOH. Ca²⁺ free Tyrode solution contain (in mM): 154
225 NaCl, 4 KCl, 1 MgCl₂, 5.5 D-glucose, 5 HEPES, 10 2,3-Butanedione monoxime, 5 taurine, pH 7.34. All
226 drug-containing solutions are prepared fresh before the experiments and Tyrode solutions are
227 oxygenated (O₂ 100%) before each experiment. Unless otherwise specified, all reagents for cells
228 isolation and experiments are purchased from Sigma-Aldrich.

229 4.3 Adult rat ventricular cells isolation

230 Isolated cardiomyocytes are obtained from the hearts of adult rats (200–300 g body wt) according
231 to the previously described method [23,24]. Briefly, after sacrifice, the rat hearts are explanted, washed
232 in Ca²⁺ free Tyrode solution and cannulated via the aorta. All the following operations are carried on
233 under a laminar flow hood. The heart is perfused at a constant flow rate of 10 ml/min with Ca²⁺ free
234 Tyrode solution (37°C) with a peristaltic pump for approximately 5 min to wash away the blood and
235 then with 10 ml of Ca²⁺ free Tyrode supplemented with collagenase (0.3mg/ml) and protease
236 (0.02mg/ml). Hearts are then perfused and enzymatically dissociated with 20ml of Ca²⁺ free Tyrode
237 containing 50µM CaCl₂ and the same enzymatic concentration as before. Atria and ventricles are then
238 separated and the ventricles are cut in small pieces and shaken for 10 minutes in 20ml of Ca²⁺ free
239 Tyrode solution in presence of 50µM CaCl₂, collagenase and protease. Calcium ions concentration is
240 slowly increased to 0.8mM. Cardiomyocytes are then plated on glass cover slips or glass bottom
241 dishes (Ibidi, Germany), both treated with laminin to allow cell adhesion.

242 4.4 Cell viability

243 Cell viability is evaluated by propidium iodide (PI) staining on glass bottom dishes adherent
244 cells. At the end of the treatments cells are incubated with PI (10µg/ml, Invitrogen) for 5 min in the
245 dark. Nuclei of suffering cells are detected with confocal microscopy using Olympus Fluoview 200
246 microscope at 568nm (magnification 20X). Merged images are created with ImageJ (Rasband, W. S.,
247 ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, <https://imagej.nih.gov/ij/>, 1997-
248 2017) and cells viability is calculated as percentage of (total cells-labeled cells)/total cells.

249 4.5 Evaluation of sarcomere length

250 Cardiomyocytes on glass coverslips are stimulated with TMAO and H₂O₂, as a positive control.
251 Cells are treated for 24 h with TMAO, at 100µM and 10mM, then the sarcomere protein α -actinin,
252 localized in the Z lines, has been detected using confocal microscopy. Then cells are fixed in 4% PFA
253 for 40 min. After two washes with PBS, cells are incubated for 20 min with 0.3% Triton and 1% bovine
254 serum albumin (BSA) in PBS and stained for 24 h at +4°C with a mouse monoclonal anti- α -actinin
255 primary antibody (Sigma, 1:800). Cover slides are washed twice with PBS and incubated 1 h at room

256 temperature with the secondary antibody (1:2000, anti-mouse Alexa Fluor 568, Thermo Fisher). After
257 two washes in PBS, coverslips are mounted on standard slides with DABCO and observed after 24 h
258 under confocal microscope. Confocal fluorimetric measurements are acquired using a Leica SP2 laser
259 scanning confocal system, equipped with a 40X water-immersion objective. Image processing and
260 analysis are performed with ImageJ software. Sarcomere length is evaluated measuring the distance
261 between Z lanes in n=10 sarcomeres/cell.

262 4.6 Intracellular Reactive Oxygen Species (ROS) measurement

263 Production of ROS is evaluated by fluorescence microscopy using the 2'-7'-Dichlorofluorescein
264 diacetate probe (DCF-DA). After adhesion on glass bottom dishes, DCF-DA solution (5µg/ml) is
265 added to each dish 30min prior to the end of the treatment, then cells are washed with standard
266 Tyrode solution. Fluorescence images at 488nm have been acquired with Olympus Fluoview 200
267 microscope (magnification 60X). Fluorescence variations are calculated with the definition and
268 measurement of Regions Of Interest (ROIs) using the software ImageJ and expressed as relative
269 Medium Fluorescence Index (MFI) compared to control, fixed at 1.

270 4.7 Mitochondrial membrane potential measurement

271 Mitochondrial membrane potential is evaluated by staining cardiomyocytes with the dye
272 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide (JC-1). JC-1 solution (10µM) is
273 added to each dish 30 min prior to the end of the treatment, then cells are washed with Tyrode
274 standard. Fluorescence images at 488nm and 568nm have been acquired with Olympus Fluoview 200
275 microscope (magnification 60X). Amounts of the monomeric form of the dye are quantified using the
276 red/green fluorescence ratio in the ROIs using the software ImageJ and expressed as folds towards
277 control, fixed at 1.


278 4.8 ~~Statistical~~Statistical analysis

279 All data are expressed as mean±Standard Errors of the mean. For differences between mean
280 values Bonferroni's multiple comparisons test has been performed. Differences with P<0.05 are
281 regarded as statistically significant.

282 5. Conclusions

283 In summary, this study demonstrates that TMAO is not directly involved in causing or
284 exacerbating cardiac damage in an acute stress model (Fig. 7). However, there are some limitation of
285 this study: a very wide range of plasmatic TMAO concentrations is presented in literature, ~~and even~~
286 within different mammals, ~~and also between different sexes of the same species~~, several orders of
287 magnitude can be considered physiological [24,25,26], so, to test direct effect of the molecule, it has
288 been used high concentrations, even over human physiological ones. Another weakness of the study
289 could be linked to the time of treatment, because evaluations are no longer than 24 h and they could
290 only represent an acute exposure to TMAO. ~~Moreover, in~~ order to evaluate more deeply the
291 mechanism involved in TMAO-mediated responses it could be necessary to treat cells for longer time
292 to assess a chronic stress compatible with the development of CVD. ~~Furthermore we only study~~
293 ~~TMAO effect on female ventricular cardiomyocytes and it could be interesting to extend the analysis~~
294 ~~also to male cardiomyocytes as gender differences have been observed in cardioprotective~~
295 ~~mechanisms [27] and TMAO induced intracellular calcium imbalance has been described in male~~
296 ~~cardiomyocytes [8].~~ Finally, our findings provide new insights into cardiac effect of TMAO, exploring
297 the direct treatment of isolated cardiomyocytes.

Formatted: Strikethrough



298
299 **Figure 7.** No effects of TMAO is detectable on isolated adult rat cardiomyocytes viability, sarcomere
300 length, ROS production and mitochondrial membrane potential (MMP).

301 **Author Contributions:** MG and RL conceived the study, assisted its design and revised the manuscript for
302 important intellectual content. GQ and SA carried out all the experiments, statistical analysis, all the authors
303 interpreted the results. GQ wrote the manuscript. All authors read and approved the final manuscript.

304 **Funding:** This research received no external funding, it was supported by the local funding of the University of
305 Turin (Maria Pia Gallo and Renzo Levi). The APC was funded by Maria Pia Gallo and Renzo Levi.

306 **Acknowledgments:** The Authors acknowledge Dr. Nunzio Dibiase for his technical support.

307 **Conflicts of Interest:** The authors declare no conflict of interest.

308 Abbreviations

TMAO	Trimethylamine N-oxide
PI	Propidium iodide
ROS	Reactive Oxygen Species
DCF-DA	2'-7'-Dichlorofluorescein diacetate
JC-1	5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide

309 References

- 310 1. Ufnal, M.; Zadlo, A.; Ostaszewski, R. TMAO: A small molecule of great expectations. *Nutrition* **2015**, *31*(11),
311 1317–1323. <https://doi.org/10.1016/j.nut.2015.05.006>
- 312 2. Yancey, P. H. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high
313 osmolarity and other stresses. *Journal of Experimental Biology* **2005**, *208*(Pt 15), 2819–2830.
314 <https://doi.org/10.1242/jeb.0173>
- 315 3. Ke, Y.; Li, D.; Zhao, M.; Liu, C.; Liu, J.; Zeng, A.; Shi, X.; Cheng, S.; Pan B.; Zheng, L.; Hong, H. Gut flora-
316 dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging
317 through oxidative stress. *Free Radical Biology & Medicine* **2018**, *116*, 88–100.
318 <https://doi.org/10.1016/j.freeradbiomed.2018.01.007>
- 319 4. Li, T.; Chen, Y.; Gua, C.; Li, X. Elevated Circulating Trimethylamine N-Oxide Levels Contribute to
320 Endothelial Dysfunction in Aged Rats through Vascular Inflammation and Oxidative Stress. *Frontiers in*
321 *Physiology* **2017**, *8*. <https://doi.org/10.3389/fphys.2017.00350>
- 322 5. Zhu, W.; Gregory, J. C.; Org, E.; Buffa, J. A.; Gupta, N.; Wang, Z.; Li, L.; Fu, X.; Wu, Y.; Mehrabian, M.;
323 Balfour Sartor, R.; McIntyre, T. M.; Silverstein, R. L.; Tang, W. H. W.; DiDonato, J. A.; Brown, J. M.; Lusa,

- 324 A. J.; Hazen, S. L. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.
325 *Cell* **2016**, *165*(1), 111–124. <https://doi.org/10.1016/j.cell.2016.02.011>
- 326 6. Shan, Z.; Sun, T.; Huang, H.; Chen, S.; Chen, L.; Luo, C.; Yang, W.; Yang, X.; Yoa, P.; Cheng, J.; Hu, F. B.;
327 Liu, L. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes.
328 *The American Journal of Clinical Nutrition* **2017**, *ajcn*157107. <https://doi.org/10.3945/ajcn.117.157107>
- 329 7. Makrecka-Kuka, M.; Volska, K.; Antone, U.; Vilskersts, R.; Grinberga, S.; Bandere, D.; Liepinsh, E.;
330 Dambrova, M. Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria.
331 *Toxicology Letters* **2017**, *267*, 32–38. <https://doi.org/10.1016/j.toxlet.2016.12.017>
- 332 8. Savi, M.; Bocchi, L.; Bresciani, L.; Falco, A.; Quaini, F.; Mena, P.; Brighenti, F.; Crozier, A.; Stilli, D.; Del Rio,
333 D. Trimethylamine-N-Oxide (TMAO)-Induced Impairment of Cardiomyocyte Function and the Protective
334 Role of Urolithin B-Glucuronide. *Molecules* **2018**, *23*(3), 549. <https://doi.org/10.3390/molecules23030549>
- 335 9. Arduini, A.; Zammit, V. A.; Bonomini, M. Identification of trimethylamine N-oxide (TMAO)-producer
336 phenotype is interesting, but is it helpful? *Gut* **2019**, *0*, 1. <https://doi.org/10.1136/gutjnl-2018-318000>
- 337 10. Nowiński, A.; Ufnal, M. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle
338 diseases? *Nutrition* **2018**, *46*, 7–12. <https://doi.org/10.1016/j.nut.2017.08.001>
- 339 11. Dumas, M.-E.; Maibaum, E. C.; Teague, C.; Ueshima, H.; Zhou, B.; Lindon, J. C.; Nicholson, J. K.; Stampler,
340 J.; Elliott, P.; Chan, Q.; Holmes, E. Assessment of analytical reproducibility of 1H NMR spectroscopy based
341 metabonomics for large-scale epidemiological research: the INTERMAP Study. *Analytical Chemistry* **2006**,
342 *78*(7), 2199–2208. <https://doi.org/10.1021/ac0517085>
- 343 12. Collins, H. L.; Drazul-Schrader, D.; Sulpizio, A. C.; Koster, P. D.; Williamson, Y.; Adelman, S. J.; Owen, K.;
344 Sanli, T.; Bellamine, A. L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with
345 low aortic lesions in ApoE^{-/-} transgenic mice expressing CETP. *Atherosclerosis* **2016**, *244*(C), 9–37.
346 <https://doi.org/10.1016/j.atherosclerosis.2015.10.108>
- 347 13. Lupachyk, S.; Watcho, P.; Stavniichuk, R.; Shevalye, H.; Obrosova, I. G. Endoplasmic Reticulum Stress
348 Plays a Key Role in the Pathogenesis of Diabetic Peripheral Neuropathy. *Diabetes* **2013**, *DB*_120716.
349 <https://doi.org/10.2337/db12-0716>
- 350 14. Zeisel, S. H.; Warriar, M. Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease. *Annual*
351 *Review of Nutrition* **2017**, *37*, 157–181. <https://doi.org/10.1146/annurev-nutr-071816-064732>
- 352 15. Sarvazyan, N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. *The*
353 *American Journal of Physiology* **1996**, *271*(5 Pt 2), H2079-2085.
354 <https://doi.org/10.1152/ajpheart.1996.271.5.H2079>
- 355 16. Zununi Vahed, S.; Barzegari, A.; Zuluaga, M.; Letoumeur, D.; Pavon-Djavid, G. Myocardial infarction and
356 gut microbiota: an incidental connection. *Pharmacological Research* **2018**, *129*, 308-317.
357 <http://doi.org/10.1016/j.phrs.2017.11.008>

- 358 17. Cho, C. E.; Taesuwan, S.; Malysheva, O. V.; Bender, E.; Tulchinsky, N. F.; Yan, J.; Sutter, J. L.; Caudill, M.
359 A. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men
360 and is influenced by their gut microbiota composition: A randomized controlled trial. *Molecular Nutrition*
361 *& Food Research* **2017**, *61*(1). <https://doi.org/10.1002/mnfr.201600324>
- 362 18. Ufnal, M.; Jazwiec, R.; Dadlez, M.; Drapala, A.; Sikora, M.; Skrzypecki, J. Trimethylamine-N-oxide: a
363 carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. *The Canadian*
364 *Journal of Cardiology* **2014**, *30*(12), 1700–1705. <https://doi.org/10.1016/j.cjca.2014.09.010>
- 365 19. Koeth, R. A.; Wang, Z.; Levison, B. S.; Buffa, J. A.; Org, E.; Sheehy, B. T.; Britt, E. B.; Fu, X.; Wu, Y.; Li, L.;
366 Smith, J. D.; DiDonato, J. A.; Chen, J.; Li, H.; Wu, G. D.; Lewis, J. D.; Warriar, M.; Brown, J. M.; Krauss, R.
367 M.; Tang, W. H. W.; Bushman, F. D.; Lusis, A. J.; Hazen, S. L. Intestinal microbiota metabolism of L-
368 carnitine, a nutrient in red meat, promotes atherosclerosis. *Nature Medicine* **2013**, *19*(5), 576.
369 <https://doi.org/10.1038/nm.3145>
- 370 20. Dambrova, M.; Latkovskis, G.; Kuka, J.; Strele, I.; Konrade, I.; Grinberga, S.; Hartmane, D.; Pugovics, O.;
371 Erglis, A.; Liepinsh, E. Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels.
372 *Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and]*
373 *German Diabetes Association* **2016**, *124*(4), 251–256. <https://doi.org/10.1055/s-0035-156933>
- 374 21. Mueller, D. M.; Allenspach, M.; Othman, A.; Saely, C. H.; Muendlein, A.; Vonbank, A.; Drexel, H.; von
375 Eckardstein, A. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and
376 poor metabolic control. *Atherosclerosis* **2015**, *243*(2), 638–644.
377 <https://doi.org/10.1016/j.atherosclerosis.2015.10.091>
- 378 22. Yin, J.; Liao, S.-X.; He, Y.; Wang, S.; Xia, G.-H.; Liu, F.-T.; Zhu, J.-J.; You, C.; Chen, Q.; Zhou, L.; Pan, S.-Y.;
379 Zhou, H.-W. Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With
380 Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. *Journal of the American Heart Association*
381 **2015**, *4*(11). <https://doi.org/10.1161/JAHA.115.002699>
- 382 [23. Huc, T.; Drapala, A.; Gawrys, M.; Konop, M.; Bielinska, K.; Zaorska, E.; Samborowska, E.; Wyczalkowska-](#)
383 [Tomasik, A.; Paczek, L.; Dadlez, M.; Ufnal, M. Chronic, low-dose TMAO treatment reduces diastolic](#)
384 [dysfunction and heart fibrosis in hypertensive rats. *American Journal of Physiology Heart and Circulatory*](#)
385 [Physiology](#) **2018**, *315*, H1805-H1820. <https://doi.org/10.1152/ajpheart.00536.2018>
- 386 [23-24. Gallo, M. P.; Femminò, S.; Antoniotti, S.; Querio, G.; Alloatti, G.; Levi, R. Catestatin induces glucose](#)
387 [uptake and GLUT4 trafficking in adult rat cardiomyocytes. *BioMed Research International*](#) **2018**,
388 <https://doi.org/10.1155/2018/2086109>
- 389 [24-25. Lenky, C. C.; McEntyre, C. J.; Lever, M. Measurement of marine osmolytes in mammalian serum by](#)
390 [liquid chromatography-tandem mass spectrometry. *Analytical Biochemistry*](#) **2012**, *420*, 7-12.
391 <https://doi.org/10.1016/j.ab.2011.09.013>
- 392 [25-26. Somero, G. N.; From dogfish to dogs: trimethylamines protect proteins from urea. *American Journal*](#)
393 [of Physiology](#) **1986**, *1*, 9-12. <https://doi.org/10.1152/physiologyonline.1986.1.1.9>

Formatted: Hyperlink, Font: Calibri, 12 pt

Formatted: Hyperlink, Font: Times New Roman, 12 pt, English (United States)

394 [27. Lagranha, C. L.; Deschamps, A.; Aponte, A.; Steenbergen, C.; Murphy, E. Sex differences in the](#)
395 [phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and](#)
396 [cardioprotection on females. Circulation Research 2010, 106\(11\), 1981-91.](#)
397 <http://doi.org/10.1161/CIRCRESAHA.109.213645>
398

399
400



© 2019 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

401